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Review article
The role of the intestinal microbiota in the development of atopic
disorders
The role of the gut microbiota in health and disease has
received considerable scientiﬁc interest recently. Especi-
ally, the development of new culture-independent tech-
niques has rekindled the interest in intestinal microbial
ecology. The gut microbiota has been linked to the risk of
gastrointestinal diseases such as inﬂammatory bowel
diseases (IBD) (1–4), irritable bowel syndrome (IBS)
(5, 6) and necrotizing enterocolitis (7–9). However the
role of the gut microbiota in health and disease may go
even beyond the gut as it has also been linked to atopic
diseases. This review aims to give a comprehensive
overview of observational studies of the association
between the gut microbiota composition and atopic
disorders, with a special focus on the methods used to
characterize this microbiota.
The commensal microbiota of the gastrointestinal tract
The fetal intestine is sterile and bathed in swallowed
amniotic ﬂuid. Following delivery, the colonization of the
intestines by a variety of microorganisms begins (10).
Gastrointestinal colonization involves a succession of
bacterial populations waxing and waning as the diet
changes and the host develops (11). This assemblage of
bacteria inhabiting the gut is usually referred to as the
commensal intestinal microbiota. Each human adult
harbors approximately 1014 bacteria in the gut, which is
about 10 times the number of cells making up the human
body (12). There are at least 400–500 diﬀerent bacterial
species and these species can again be divided into
diﬀerent strains, highlighting the enormous complexity of
this ecosystem. Furthermore the composition of this
microbiota diﬀers depending on their location in the gut.
The concentration of bacteria ranges from 103 colony-
forming units per millilitre (CFU/ml) in the stomach,
where the number of ingested bacteria is dramatically
reduced by contact with gastric acid, to 1011–1012 CFU/ml
in the colon (Fig. 1) (13). The colonic microbiota is
dominated by obligatory anaerobes such as Bacteroides
spp., Clostridium spp., biﬁdobacteria, eubacteria, and
fusobacteria. Facultative anaerobes occur in 100- to 1000-
fold lower numbers and include lactobacilli, enterococci,
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streptococci and Enterobacteriaceae (Table 1) (12, 14). In
addition to variations in the composition of the micro-
biota along the axis of the gastrointestinal tract, surface-
adherent and luminal microbial populations also diﬀer
(15). Bacteria may be free-living in the lumen or attached
to the mucus, mucosal surface, food particles or digestive
residues. The attached bacteria produce microcolonies,
leading to the development of bioﬁlms which initially may
be composed of only one bacterial species, but frequently
develop into a complex community composed of diﬀerent
bacterial species (16).
Factors inﬂuencing the intestinal microbiota composi-
tion can be divided into host factors (such as pH, transit
time, bile acids, pancreatic enzymes and mucus compo-
sition), non-host factors (such as nutrients, medication
and environmental factors), and bacterial factors (such as
adhesion capacity, enzymes and metabolic capacities)
(17). The bacteria in the gut interact with their human
host, and although some bacteria are potentially patho-
genic and can become a source of infection and sepsis,
this host–bacterial interaction is mainly symbiotic. The
host provides a nutrient-rich environment and the bac-
teria can confer important health beneﬁts upon the
human host (18). Probably the most important function
of the gut microbiota is the so-called colonization
resistance. By not only competing for nutrients and
adhesion sites, but also by the production of antibacterial
substances (bacteriocins), the indigenous gut microbiota
makes it diﬃcult for potentially pathogenic bacteria to
colonize. Other important functions are the fermentation
of non-digestible dietary residues and endogenous mucus,
salvage of energy as short-chain fatty acids, production of
vitamin K and absorption of ions (18).
Furthermore the gut-associated lymphoid tissue
(GALT) is the largest immune organ of the human body,
which is exposed to an enormous dietary and bacterial
antigenic load. Studies of germ-free animals have shown
that the gut microbiota plays an important role in the
development of the gastrointestinal immune system.
Germ-free animals have among others decreased Peyers
patch size, decreased number of IgA-producing lympho-
cytes in the lamina propria, decreased number of intra-
epithelial T cells and a delayed immune response after
antigenic challenge compared with conventional animals
(12, 19–23).
From culture to genotype analysis
Research into the intestinal microbiota composition has
relied almost exclusively on the quantitative culture of
microbes from fecal samples. Enumeration of particular
microbial genera or species relies on the use of selective
culture media. The analysis of the composition of the
normal microbiota using these media is undoubtedly
biased by the inability to culture all of the microbes
present in samples (about 40–80% of bacteria as seen by
microscopy cannot be cultured), the fact that few selective
media are absolutely selective and that these media do not
always equally support the growth of diﬀerent species
comprising a population. Even when culturable, the
identiﬁcation to species level using biochemical tests
requires experience and is subject to intuitive interpreta-
tions (18, 24). Another major disadvantage in using
classical culturing techniques in large-scale epidemiolog-
ical studies is that samples require immediate processing
(25). The relative inexpensiveness and wide availability on
the other hand make these classical techniques the most
applied.
The development of molecular techniques to investi-
gate ecological microbial communities has provided the
microbiologist with a vast array of new techniques to
study the human intestinal microbiota. With these
techniques, unculturable species are detectable, anaer-
obic handling and expertise are not required and
samples can be kept frozen for later analysis (25).
Analysis of bacterial communities using molecular
techniques has so far targeted 16S rRNA gene sequences
because the small ribosomal sub-unit RNA (16S rRNA
in the case of bacteria) contains regions of highly
conserved nucleotide base sequences interspersed with
hypervariable regions (26). These hypervariable regions
contain the signatures of phylogenetic groups, and,
sometimes even species.
Table 1. The most important genera in the human intestinal tract
Obligatory anaerobic genera Facultative anaerobic genera
Bifidobacteria G+ Lactobacilli G+
Clostridia G+ Enterococci G+
Eubacteria G+ Streptococci G+
Bacteroides G) Staphylococci G+
Fusobacteria G) Enterobacteria G)
G), gram-negative; G+, gram-positive.
Figure 1. Bacterial densities increase throughout the gut, with
highest concentrations found in the colon.
Penders et al.
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Fluorescence in situ hybridization (FISH), polymerase
chain reaction (PCR) combined with denaturing- or
temperature-gradient gel electrophoreses (PCR-DGGE/
PCR-TGGE) and real-time PCR are molecular tech-
niques which have found application for studying gut
microbiota (27). These techniques all have their advan-
tages and limitations. FISH is based on the use of
ﬂuorescent oligonucleotide probes targeting 16S ribo-
somal RNA sequences of intact bacterial cells. Technical
diﬃculties can inﬂuence the accuracy of the results.
Probes must reach their target sequence, which is inside
the bacterial cell, bypassing the cell wall. Gram-positive
bacterial cells such as lactobacilli, for example, are more
diﬃcult to permeabilize than others (28). Furthermore
this method is rather insensitive with detection limits of
106 bacterial cells per gram. This technique is particularly
useful to visualize the spatial distribution of microbes
within the intestinal ecosystem.
Another molecular method is PCR-TGGE/-DGGE. In
this method of analysis, bacterial DNA is extracted from
the fecal sample and fragments of the 16S rRNA gene are
ampliﬁed by PCR; subsequently the 16S molecular
species within the resulting mixture are separated by
TGGE/DGGE. The double-stranded 16S fragments
migrate through the polyacrylamide gel until each kind
of fragment is partially denatured by the prevailing
temperature or chemical conditions (26, 28). The advant-
age of PCR-DGGE/-TGGE is that it generates a bacter-
ial ﬁngerprint of the dominant bacteria in a sample.
Knowledge about the bacterial composition is unneces-
sary. The technique is however not quantitative, rather
insensitive and very laborious, making it unsuitable for
analysis of large numbers of samples.
The quantitative real-time PCR method monitors the
amount of PCR products of DNA as they are ampliﬁed
by the use of ﬂuorescent oligonucleotide probes. The
ﬂuorescence intensity emitted during the ampliﬁcation
process reﬂects the amplicon concentration in real time.
From the change of amplicon concentration throughout
the ampliﬁcation cycles, the initial concentration of the
target DNA/RNA can be estimated (29, 30). Real-time
PCR lends itself well as a tool for the quantiﬁcation
of intestinal populations as it combines the speciﬁcity of
ﬂuorescent oligonucleotide probes with the sensitivity of
PCR (28). Care should however be taken regarding the
method used for DNA/RNA extraction, as DNA/RNA
may not be extracted with equal eﬃciency from all
bacteria (13).
The microbiota hypothesis in atopy
Very recently it was hypothesized that the gut microbiota
may also be involved in the etiology of atopic diseases.
Atopic diseases are chronic inﬂammatory disorders
caused by aberrant T-helper 2 (Th2)-type immune
responses against common innocuous environmental
antigens (allergens) in susceptible individuals (31). The
worldwide rise in atopic diseases (eczema, food allergy,
hay fever and asthma) was most predominant in the
westernized countries and occurred in such a pace that
this could never be solely explained by changes in
the genetic make-up (32, 33). Therefore the causes
of the atopic epidemic are generally believed to be of
environmental origin. In 1989 Strachan hypothesized that
this increase in atopic disease was the result of a lack of
infections in early infancy. This hypothesis was based
upon Strachans observations that infants with higher
number of siblings were at decreased risk for developing
atopy (34). Although sibship size (35, 36), and other
indirect markers of microbial exposure such as rural and
farm-living (especially contact with livestock) (37, 38)
were consistently shown to be associated with a decreased
risk of developing allergies, studies of the association
between viral and bacterial infections and allergy were
less consistent (38, 39). In 1998 Wold suggested that
rather than a decrease in viral or bacterial infections, an
altered normal intestinal colonization pattern in infancy,
which fails to induce immunological tolerance, could be
responsible for the increase in allergies (40). This idea of a
potential role of the gut microbiota was based on the
observations that (i) it is diﬃcult to achieve oral tolerance
in germ-free animals (41); (ii) administration of lipopoly-
saccharide (LPS; a constituent of the outer membrane of
gram-negative bacteria) together with food antigens
increases the tolerizing eﬀect of feeding (42); (iii) and
bacterial toxins may break oral tolerance (43). Since then,
several observational studies of the gut microbiota
composition and allergy have been conducted.
Potential immunological mechanisms
The innate immune system may be decisive in determin-
ing the type of adaptive immune responses elicited against
microbial antigens. Of the innate immune cells, dendritic
cells (DC) seem to be pivotal in the earliest bacterial
recognition and in shaping T-cell responses (44). Innate
immune cells recognize microbial antigens through mol-
ecules such as Toll-like receptors (TLRs), and nucleotide-
binding oligomerization domain (NODs) molecules,
which recognize conserved pathogen-associated molecu-
lar patterns, including unmethylated CpG motifs charac-
teristic of bacterial DNA, the bacterial LPS and
peptidoglycan (45).
The initial immunological explanation for the hygiene
hypothesis was a lack of microbial antigen-induced
immune deviation from the Th2 cytokine proﬁle to a
Th1-type proﬁle, resulting in the development of enhanced
Th2-cell responses to allergens (46–48). However, this
explanation did not take into account that the prevalence
of Th1-associated diseases, such as Crohns disease, type 1
diabetes and multiple sclerosis, was also increasing and
that chronic parasitic worm (helminth) infections which
induce strong Th2 responses and high IgE levels are not
associated with an increased risk of allergy (49).
Intestinal microbiota and atopic disorders
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An alternative interpretation conceives anti-inﬂamma-
tory immune responses to be of fundamental importance
in the development of mucosal and systemic tolerance
(50). These immunosuppressive mechanisms are orches-
trated by regulatory T-cell classes (Treg cells) that control
[largely via the production of interleukin (IL)-10 and/or
tumor growth factor (TGF)-b] both Th1 and Th2
responses and hence the development of both atopic
and autoimmune diseases (50, 51). Indeed the importance
of a delicate balance between allergen-speciﬁc Treg cells
and allergen-speciﬁc Th2 cells in healthy and allergic
immune responses to common environmental allergens
was demonstrated in a study conducted by Akdis et al.
(52). Furthermore, a study of duodenal biopsies of
healthy infants and infants with multiple food allergy
showed that the dominant mucosal abnormality was not
Th2 deviation but impaired generation of TGF-b-produ-
cing Treg cells (53).
Relatively harmless organisms, including not only
biﬁdobacteria and lactobacilli, but also helminths and
saprophytic mycobacteria, may skew immune responses
toward immunoregulation by inducing Treg cells, rather
than eliciting a proinﬂammatory immune response. For
example, Lactobacillus paracasei has been reported to
inhibit the secretion of both Th1 and Th2 cytokines, while
inducing the development of a population of CD4(+)
T cells producing TGF-b and IL-10, reminiscent of
previously described subsets of regulatory cells implicated
in oral tolerance and gut homeostasis (54).
Lactobacillus reuteri and Lactobacillus casei have been
shown to prime monocyte-derived DCs to drive the
development of IL-10-producing Treg cells, through bind-
ing of the C-type lectin DC-speciﬁc intracellular adhesion
molecule 3-grabbing non-integrin (DC-SIGN) (55). The
Biﬁdobacterium genomicDNAhas been reported to induce
the secretion of IL-10 by peripheral blood mononuclear
cells (PBMCs) from healthy donors in vitro (56).
The microbiota hypothesis proposes that the loss of
exposure to these harmless microorganisms in the west-
ernized environment might explain the increase in
immune dysregulatory disorders (57, 58). The epidemio-
logical ﬁndings and the experimental evidence available
so far suggest that both the reduced immune suppression
by Treg cells and the lack of immune deviation from a
Th2 to Th1 proﬁle are involved (59). Furthermore, the
impact of the gut microbiota on the development of IgA
antibody responses, which contribute to pathogen and
allergen exclusion in the gut lumen, may also be involved
(45).
It has been proposed that the eﬀects of the gut
microbiota may not only be related to food antigens,
but also to aeroallergens and the manifestation of allergic
airway symptoms. Noverr et al. developed a mouse model
to demonstrate experimentally that antibiotic therapy,
leading to bacterial and fungal microbiota changes, could
predispose a host to allergic airway disease (60). Further-
more, oral treatment with live L. reuteri has recently been
shown to inhibit the allergic airway response in mice (61).
These results support the possibility that aﬀerent events
in allergic sensitization may occur outside of the lungs
and involve host–microbiota communication.
The mechanisms by which events in the gut can aﬀect
the systemic immune system and local inﬂammation in
remote tissues such as the respiratory tract remain to be
determined. However, it has been shown that inhaled
particles, ﬂuids and microbes are also swallowed. The
gastrointestinal tract will, thus, be exposed to any
antigens to which the respiratory tract is also exposed.
As ingestion of antigens can induce tolerance to that
antigen (oral tolerance), the gastrointestinal (GI) tract
may act as a sensor for the development of tolerance to
inhaled antigens (11, 62). Induced regulatory T cells may
thereafter home in other tissues throughout the body, in
particular in other mucosal tissues such as the respiratory
tract (63).
Methods of literature review
Observational studies comparing healthy and allergic subjects (de-
ﬁned as subjects with atopic eczema/dermatitis, food allergy,
wheeze, allergic rhinitis, asthma and/or sensitization) regarding the
(quantitative) presence of intestinal bacteria, were included in this
review. Intervention studies on the eﬀects of probiotics, prebiotics
and synbiotics in the treatment or prevention of allergic diseases are
beyond the scope of this review, as these studies have to deal with
completely diﬀerent methodological issues. For an overview of
studies on the use of probiotics in the prevention and treatment of
allergic diseases we refer to an extensive review on this topic (64).
The publications were analyzed for population size, design of the
study, atopic outcomes, and methods used for analyzing the fecal
samples.
To identify all observational studies on the association between
the gut microbiota composition and atopic disorders, a literature
search was performed by searching the databases of Medline,
EMBASE and PubMed up to January 2007. The following key-
words and limits were used: [intestines (mesh) OR intestin* OR gut
OR gastrointestin* OR enteric] AND (ﬂora OR microbiolog* OR
microﬂora OR bacteria OR bacterial OR colonization OR coloni-
sation OR microbes OR microbial OR microbiota) AND (hyper-
sensitivity OR atopic dermatitis OR allergic OR allergy OR atopic
OR atopy OR eczema OR rhinitis OR asthma) AND [English(la)].
Additional reports were found searching the reference lists of per-
tinent articles.
Results
Using the search criteria as described above, we identiﬁed
18 observational studies on the association between the
gut microbiota and atopic diseases. Eight studies were
exclusively based on traditional bacteriological culture
techniques to study the microbial composition of fecal
samples, and another seven studies (additionally) used
molecular techniques. The remaining three studies were
not based on the examination of fecal samples, but tested
for IgG seropositivity to certain intestinal microbes. All
Penders et al.
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studies, except one, are presented and compared in
Table 2 according to the type of atopic disease under
study, the study population, design and methodology to
examine the intestinal microbiota. One study (65) was not
incorporated in Table 2, because it lacked statistical
analysis and a reference group.
Culture-dependent studies
Already in the early 1980s, Russian scientists linked food
allergy to abnormal intestinalmicrobiota (65). The authors
examined 60 infants with dermatological syndrome,
caused by food allergy and reported dysbacteriosis of
diﬀerent degrees in all cases. This dysbacteriosis was
characterized by a deﬁciency of biﬁdobacteria and lacto-
bacilli combined with an increase of Enterobacteriaceae.
The study however lacked statistical analysis and it was not
clear how a deﬁciency of lactic acid bacteria and an
increase of Enterobacteriaceae were deﬁned, as data
pertaining to a reference group of infants without derma-
tological symptoms was not mentioned in the paper.
It was not until the late 1990s when Sepp et al.
initiated the research into the potential role of the gut
microbiota in the etiology of allergic diseases. They
studied the gut microbiota of 1-year-old healthy infants
in Estonia with a low prevalence and Sweden with a high
prevalence of childhood allergy (66). Especially lactoba-
cilli and eubacteria were more prevalent in Estonian
infants. Swedish infants harbored higher counts of
clostridia, and especially Clostridium diﬃcile was more
common than in Estonian infants. These observations led
to the ﬁrst case–control study comparing the gut
microbiota composition of allergic infants with that of
healthy infants (Table 2). In this cross-sectional study
2-year-old allergic and non-allergic infants from Estonia
and Sweden were compared (67). Allergic infants were
less often colonized by lactobacilli compared with non-
allergic infants in both countries. In contrast, the allergic
children harbored higher counts of facultative aerobic
microorganisms, especially coliforms in the Estonian and
Staphylococcus aureus in the Swedish children. The
number of study subjects was relatively low (27 allergic
and 35 non-allergic subjects); therefore diﬀerences other
than country of origin could not be taken into account.
This was the ﬁrst study to demonstrate diﬀerences in the
gut microbiota between healthy and allergic infants;
however as it was cross-sectional a conclusion on what
comes ﬁrst could not be drawn. Therefore in a follow-up
study, the same research group aimed at prospectively
relating the intestinal microbiota composition to the
development of allergy in 20 Swedish and 24 Estonian
infants (68). Fecal samples were collected several times
throughout the ﬁrst year of life and infants were clinically
followed up for the presence of allergic symptoms and
sensitization until the age of 2 years. The prevalence of
colonization by biﬁdobacteria was consistently lower
throughout the ﬁrst year of life in infants who developed
allergy compared with those who did not. Other diﬀer-
ences were only present at one moment during the follow
up. Especially the observation of diﬀerences between
healthy and allergic infants at only one moment has to be
interpreted with caution as comparing both prevalence
and counts of multiple bacterial groups at several
diﬀerent time points introduces a considerably risk of
false-positive ﬁndings because of multiple testing. Fur-
thermore numbers were too small for statistical analysis
for the two countries separately.
Diﬀerences in the biﬁdobacterial species composition
were ﬁrst investigated in a small Finnish case–control
study (69). In this study, faecal samples of seven breast-
fed allergic infants and six breast-fed, healthy, age-
matched controls were examined. Allergic infants were
more often colonized with Biﬁdobacterium adolescentis,
whereas colonization with Biﬁdobacterium biﬁdum was
more frequent in their healthy counterparts.
In a Japanese case–control study, among minors with
atopic dermatitis (AD) and healthy control subjects,
counts of biﬁdobacteria were lower in cases than in
healthy controls. The proportion of biﬁdobacteria in total
bacterial count was negatively correlated with the severity
of AD. Furthermore the prevalence of colonization with
staphylococci was higher in the AD group than in the
control group (70).
In another Japanese case–control study (71), fecal
samples of 11 adult atopic dermatitis patients and 14
healthy adults were compared. Although proportions of
the predominant bacteria in total bacteria were almost the
same in both groups, those of Enterobacteriaceae were
signiﬁcantly higher in AD patients than in healthy adults.
Sepp et al. studied the association between the
intestinal microbiota and immunoglobulin E responses
in 5-year-old Estonian infants. Counts of clostridia
were higher in children with speciﬁc IgE antibodies to
food and/or inhalant allergens; furthermore the relat-
ive share of clostridia was higher and that of
biﬁdobacteria lower in allergic than in non-allergic
children (72).
Recently a case–control study was published investi-
gating the gut microbiota of infants with AD with
or without sensitization to food allergens (73). No
diﬀerences were found in the intestinal microbiota
composition of infants with IgE-associated and non-
IgE-associated AD. As this study compares two sub-
groups of infants with AD and does not include a
reference group of healthy infants, it can only be
concluded that no diﬀerences exist between these sub-
groups. It may well be that both subgroups of infants
have a diﬀerent gut microbiota composition compared
with healthy infants.
These studies all provided valuable information and
especially the studies from Estonia and Sweden formed
the basis of this research area. However the fact that these
studies were solely based on culture-dependent techniques
makes them vulnerable to bias.
Intestinal microbiota and atopic disorders
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Table 2. Overview of case–control and cohort studies on the association between intestinal microbiota composition and allergy
Ref. Year Definition of allergy Study population Design
Bacteriological/
serological analyis
Results for atopic compared with
non-atopic subjects
67 Bjorksten,
1999
Atopic dermatitis (Hanifin &
Rajka) and at least 1
positive SPT
27 allergic and 35
non-allergic 2-year-old
children
Cross-sectional, nested
case–control
Bacteriological culture
and biochemical
identification
Lower prevalence of
bifidobacteria (not significant
after stratification for country)
and lactobacilli
Higher counts of coliforms (in
atopic compared to non-atopic
infants from Estonia) and
S. aureus (in atopic compared
with non-atopic infants from
Sweden)
68 Bjorksten,
2001
Atopic dermatitis (Hanifin &
Rajka) and/or at least 1
positive SPT at age 3, 6, 12
or 24 months
44 newborns (18 became
cases)
Prospective birth cohort
(until age 2 years)
Bacteriological culture
and biochemical
identification at age
1 week and 1, 3, 6
and 12 months
Lower prevalence of enterococci
(during 1st month); higher
countsof clostridia (at3 months)
Higher prevalence of S. aureus
(at 6 months)
Lower counts of bacteroides (at
12 months)
Lower prevalence of
bifidobacteria (during year 1)
75 Kirjavainen,
2001
Atopic dermatitis (Hanifin &
Rajka)
27 allergic and 10
non-allergic children
(5–13 months)
Cross-sectional,
case–control
Bacteriological culture
and FISH
No differences in concentrations
of specific genera (bacteroides,
lactobacilli/enterococci,
Clostridium difficile, E. coli),
although some genera were
associated with severity of
atopy
69 Ouwehand,
2001
Atopic dermatitis (Hanifin &
Rajka) and at least 1
positive SPT
7 allergic and 6 healthy
infants (2–7 months)
Cross-sectional
case–control
Bacteriological culture
and biochemical
identification of
bifidobacteria to the
species level
More often colonized with
Bifidobacterium adolescentis
and less often colonized with
Bifidobacterium bifidum
76 Kalliomaki,
2001
At least 1 positive SPT at
age 12 months
76 newborns at high risk of
allergy (22 became cases)
Prospective birth cohort
(until age 1 year)
Gas-liquid
chromatography,
Bacteriological culture
at age 3 weeks and
3 months and FISH
(only at 3 weeks)
Different bacterial fatty acid
profiles at 3 weeks.
No differences in prevalence of
colonization (at 3 weeks and
3 months as determined by
culture)
Lower bifidobacteria : clostridia
ratio (at 3 weeks as
determined by FISH)
74 Bottcher,
2000
At least one positive SPT at
age 12 months
25 allergic 43 non-allergic
13-month-old infants
Cross-sectional, nested
case–control
Gas chromatography Lower levels of propionic,
i-butyric, butyric, i-valeric and
valeric acid and higher levels of
i-caproic acid.
Higher relative distribution of
acetic and i-caproic acid
70 Watanabe,
2003
Atopic dermatitis (Japanese
Dermatological
Association)
30 allergic and 68
non-allergic children
Cross-sectional,
case-control
Bacteriolocical culture
and biochemical
identification
Higher prevalence of S. aureus
Lower counts of bifidobacteria
Significant trend between
percentage bifidobacteria of
total flora and severity of
atopic eczema
71 Matsumoto,
2004
Severe atopic dermatitis 11 allergic and 14 non-
allergic adults
Cross-sectional,
case–control
Bacteriological culture
and measurement of
sIgA in faeces
Lower total counts and total
anaerobes
Higher proportion of Entero-
bacteriaceae
Higer content of sIgA
Penders et al.
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Culture-independent studies
In a study of microﬂora-associated characteristics it was
shown that sensitized infants had higher levels of i-caproic
acid in their stools compared with non-sensitized infants.
This rather uncommon short-chain fatty acid was sugges-
ted to indicate the presence of C. diﬃcile (74).
Molecular techniques to quantify intestinal bacteria
were ﬁrst used in two studies conducted in Finland (75,
76). In a case–control study using FISH to characterize
Table 2. (Continued)
Ref. Year Definition of allergy Study population Design
Bacteriological/
serological analyis
Results for atopic compared with
non-atopic subjects
77 Mah, 2006 Atopic dermatitis (Hanifin &
Rajka)
21 allergic and 28
non-allergic 3-year-old
children
Cross-sectional Bacteriological culture
and biochemical
identification (for
aerobes) and FISH (for
anaerobes)
Higher counts of LAB (especially
enterococci)
Lower counts of bifidobacteria
and clostridia
79 Woodcock,
2002
Recurrent wheeze (‡3
episodes) and at least 1
positive SPT
10 allergic and 10
non-allergic 1-year-old
children
Cross-sectional (nested)
case–control
Serum IgG levels to
C. difficile
Higher levels of
C. difficile-specific IgG levels
78 Murray,
2005
Recurrent wheeze (‡3
episodes) and at least 1
positive SPT
33 allergic and 33
non-allergic 4-year old
children
Cross-sectional, nested
case–control
PCR-DGGE and FISH No difference in prevalence of
colonization with lactobacilli
and bifidobacteria. No
differences in bifidobacterial
counts (lactobacilli not
enumerated), or in
bifidobacterial species
composition
80 Linneberg,
2003
Specific serum IgE and/or
allergic rhinitis
1112 subjects (15–69 years) Cross-sectional
population-based
IgG seropositivity to
several
microorganisms
Higher prevalence of specific IgE
and allergic rhinitis in subjects
seropositive to C. difficile
81 Fukuda,
2004
Asthma, rhinitis, eczema
and/or food allergy
787 junior high school
children
Cross-sectional
population-based
Seum IgG levels to
several bacterial
species
Higher IgG levels against
B. vulgates in subjects with 2
or more symptoms
72 Sepp, 2005 Atopic dermatitis, bronchial
asthma and/or allergic
rhinitis
19 allergic and 19
non-allergic 5-year-old
children
Cross-sectional
case–control
Bacteriological culture
and biochemical
identification
Lower prevalence and proportion
of bifidobacteria, higher
proportion of clostridia. Higher
count of clostridia in infants
with specific IgE antibodies
82 Penders,
2006
Eczema (based on ISAAC-
questionnaire) specific,
serum IgE or recurrent
wheeze (‡3 episodes)
957 newborns Prospective birth cohort
(until age 2 years)
Quantitative real-time
PCR at age 1 month
Higher prevalence and counts of
E. coli in infants who
subsequently developed
eczema
Higher prevalence of C. difficile
in infants who subsequently
developed eczema, recurrent
wheeze and/or became
sensitized
83 Penders,
2006
Eczema (based on
ISAAC-questionnaire) and
specific serum IgE to
at least 1 allergen
26 allergic and 52
non-allergic 1-year old
children
Prospective nested
case–control
PCR-DGGE and
quantitative real-time
PCR at age 1 month
E. coli more prevalent in infants
who subsequently developed
IgE-associated eczema
No differneces in total bacterial
profiles
No difference in bifidobacterial
counts or in bifidobacterial
species composition.
73 Kendler,
2006
Atopic dermatitis and
specific serum IgE to
at least 1 food allergen
93 children (<7 years) with
AD (25 children without
and 68 with specific IgE)
Cross-sectional
case–control
Bacteriological culture No differences in the fecal
microbiota of infants with AD
and specific IgE compared to
infants with AD without
specific IgE
SPT, skin-prick test; FISH, fluorescence in situ hybridization; GLC, gas–liquid chromatography.
Prevalence, as percentage of infants colonized with a certain bacterial group or species.
Counts, as mean or median log10 colony-forming units per gram of feces.
Proportion, as mean or median percentage a certain bacterial group or species contributes to the total bacterial counts.
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the gut microbiota, no diﬀerences in concentrations of
speciﬁc genera were found between healthy infants and
infants suﬀering from AD. Higher bacteroides counts and
lower counts of biﬁdobacteria were however associated
with more severe manifestations of dermatitis (75). In a
cohort study prospectively following up 76 high-risk
infants during their ﬁrst year of life (76), bacterial fatty
acid proﬁles in fecal samples collected at age 3 weeks
signiﬁcantly diﬀered between infants in whom atopy
(positive skin-prick test) was or was not developing. As
bacterial culture failed to identify the bacteria possibly
responsible for these diﬀerences, FISH was additionally
used in a subpopulation of the cohort. Quantiﬁcation of
bacteria using this molecular technique demonstrated
that the atopic infants tended to have fewer biﬁdobacteria
and had more clostridia. In contrast, in a recent study
among infants in Singapore, the numbers of clostridia, as
determined by FISH, were lower in infants with eczema
compared with those in healthy controls (77). It should
however be noted that the former study only quantiﬁed
the Clostridium histolyticum subgroup, whereas the latter
study also included the Clostridium lituseburense sub-
group. The Singapore study also found biﬁdobacterial
numbers to be lower in infants with eczema, whereas
numbers of lactic acid bacteria were higher compared
with healthy controls.
Two case–control studies nested within the prospective
National Asthma Campaign Manchester Asthma and
Allergy Study (NACMAAS) investigated the association
between the intestinal microbiota composition and recur-
rent wheeze. The use of PCR combined with DGGE
showed no diﬀerences in the dominant fecal microbiota
and the biﬁdobacterial and lactobacilli composition
between sensitized wheezy and non-sensitized non-whee-
zy 4-year olds (78). In a second study within the
NACMAAS cohort, 1-year-old sensitized wheezy infants
had signiﬁcantly higher serum IgG levels against C.
diﬃcile compared with non-sensitized non-wheezy infants
(79).
The use of IgG serology to determine exposure to
intestinal microbes was also used in two large-scale
population-based cross-sectional studies (80, 81). In one
of these studies conducted in Copenhagen, both sensitized
subjects and subjects suﬀering from allergic rhinitis were
more often IgG-seropositive to intestinal bacterial path-
ogens, especially C. diﬃcile, compared with subjects
without sensitization and allergic rhinitis respectively
(80). The other study comprised 787 Japanese schoolchil-
dren and examined the association between IgG titers to
Escherichia coli, Bacteroides vulgatus, Enterococcus fae-
calis, and Biﬁdobacterium longum and allergic symptoms
(81). Infants with two or more allergic symptoms
(asthma, rhinitis, eczema and/or food allergy) had signi-
ﬁcantly higher IgG titers to B. vulgates.
The KOALA Birth Cohort Study conducted in the
Netherlands was the ﬁrst large-scale study in which the
association between the gut microbiota and atopic
manifestations has been investigated prospectively. Using
real-time quantitative PCR, fecal samples of 957 infants
have been examined. Subsequently infants were followed
up for the development of atopic symptoms (82). In this
study, colonization with E. coli was associated with an
increased risk of developing eczema in a concentration-
dependent manner. Furthermore colonization with
C. diﬃcile was associated with an increased risk of
developing eczema, recurrent wheeze and becoming
sensitized.
A case–control study nested within this same cohort
examined the intestinal microbiota of 26 infants with IgE-
associated eczema compared with 52 healthy controls
using PCR-DGGE (83). No diﬀerences were found in the
biﬁdobacterial counts and species composition. However
one band corresponding to E. coli was more prevalent in
the total bacterial proﬁles of cases compared with that of
controls.
Discussion
The microbiota hypothesis in atopic diseases is promis-
ing. Fourteen of the 17 observational studies conducted
so far indicate an association between the gut microbiota
composition and atopic sensitization or symptoms. No
speciﬁc harmful or protective microbes could however be
identiﬁed yet.
Lactobacilli are microorganisms that stimulate immu-
noregulation by triggering regulatory T-cell responses
(84). However current observational studies do not
endorse a protective role of lactobacilli; only previous
studies of Swedish and Estonian infants reported a higher
colonization by lactobacilli in non-allergic infants in both
countries (67). It should however be noted that diﬀerent
species of lactobacilli induce distinct and even opposing
DC responses with regard to their Th1/Th2/Treg-driving
capacity (85). As none of the studies identiﬁed lactobacilli
to the species level, such species-dependent eﬀects could
be overlooked.
Biﬁdobacterium spp. is also a genus which is known for
its supposed health-beneﬁcial properties and these bac-
teria may also induce immunoregulatory pathways (86).
Of the 11 studies which included the quantiﬁcation of
total biﬁdobacteria, ﬁve studies found support for a
protective eﬀect of this genus. However diﬀerences in
prevalence and counts of biﬁdobacteria between allergic
and healthy infants as found by traditional culture have
to be interpreted with caution, as especially the culture of
these bacteria is subject to bias (87). Similar to lactobacilli
the eﬀects of biﬁdobacteria may be species-dependent.
Intestinal Biﬁdobacterium species have been shown to
induce varying cytokine production by cells of the innate
immune system (88). Furthermore allergic infants have
been reported to harbor diﬀerent Biﬁdobacterium species
compared with healthy infants (69, 89). This diﬀerence
was however not conﬁrmed in the two nested case–
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control studies using Biﬁdobacterium-speciﬁc PCR-
DGGE to compare the fecal microbiota of healthy
control infants with that of IgE-associated wheezy infants
or IgE-associated eczematous infants (78, 83).
While some bacteria are associated with a reduced risk
of atopic diseases, there are also bacteria which have been
reported to be associated with an increased risk of atopic
diseases. Although ﬁndings are far from consistent,
clostridia, Enterobacteriaceae and staphylococci are
potential candidates as these have been associated with
an increased risk of atopic diseases in several studies.
Diﬀerent outcomes, diﬀerences in study design, diﬀer-
ences in the microbes under study and the methods used
to identify them, however, all make the current studies
diﬃcult to compare. Several methodological issues that
have to be considered when interpreting these studies will
now be discussed.
Critical window period
Many studies emphasize that the timing of exposure to
environmental factors may be essential to promote
beneﬁcial or harmful eﬀects regarding the development
of atopic diseases. The most important window of
opportunity for immune education seems to be in early
infancy, when the maturation of the immune system is
not yet completed and is still building up immune
tolerance against food and microbial antigens (34, 35,
45, 90). Several studies have prospectively examined the
postnatal maturation of T-helper cell responses in atopy-
prone infants and infants who did not develop atopy.
Prescott et al. demonstrated that continuation of Th2
responses (IL-4, IL-13) and decreased capacity for Th1
responses (IFN-c) to house dust mite allergen was
associated with the development of allergy, whereas
non-atopic patients showed strong Th2 responses only
at birth, but declining Th2 and increasing Th1 responses
starting within the ﬁrst 6 months of life (91). Van der
Velden et al. observed a signiﬁcantly increased produc-
tion of IL-4 at 6 months of age in children developing
atopy compared with non-atopic children, whereas this
diﬀerence was resolved at 12 months of age. This
transient increase in IL-4 production, pointing to an
active development of Th2 cells (as shown by a similarly
increased production of IL-5 and IL-13), correlated in
time with the ﬁrst clinical symptoms characteristic of an
atopic disease (AD, asthma-like disease and food or
upper-airway allergy). Therefore, the ﬁrst 6 months of life
may represent a critical time window for the initiation of
immunological changes reﬂecting allergic sensitization
(92).
This would imply that the initial gut microbiota
composition, rather than the composition later on in life,
may be considered a determinant in the development and
maintenance of normal gut barrier functions, oral toler-
ance and a disease-free state of the host (45). Indeed the
importance of timing for the eﬀect of the gut microbiota
was suggested in a number of studies of germ-free mice.
Sudo et al. demonstrated that oral administration of
ovalbumin to germ-free mice induced Th2-type cytokine-
and antigen-speciﬁc IgE production, whereas reconstitu-
tion of the intestinal microﬂora with biﬁdobacteria during
the neonatal period, but not in older age, resulted in oral
tolerance induction (41). In another study it was shown
that colonization of germ-free mice with a human gut
microbiota protected them against Escherichia coli heat-
labile enterotoxin (LT)-mediated abrogation of oral
tolerance to an unrelated co-ingested protein. This
protection was only achieved if the gut microbiota was
present from birth on (93).
Based upon this critical window period, it thus seems
unlikely that perturbations in the gut microbiota as
present beyond infancy may still have an eﬀect on the
etiology of atopic diseases. It is more likely that these
perturbations reﬂect disturbances in the gut microbiota
already present in early life. The most powerful studies on
the gut microbiota and atopic disorders are therefore
those quantifying the microbial composition in early life.
Timing and number of samples
Although the exact window of opportunity is not known,
the ideal timing for studying the intestinal microbiota
composition seems to be somewhere during the ﬁrst year
of life (94). Collecting several samples per infant during
this ﬁrst year of life can give more information than when
only one sample is collected. Furthermore, this reduces
the risk that the sample is collected outside of the window
of opportunity. However, as mentioned before, analyzing
several bacterial groups and species in several samples per
infant and relating this to several atopic outcomes result
in an increased risk of false-positive ﬁndings because of
multiple testing. The number of samples collected per
infant and the age at which these samples are collected are
thus of major importance.
An important aspect to take into account when
choosing the age at which samples are collected is the
developmental process of the gut microbiota composi-
tion. This process can be divided into four separate
phases (95). Phase 1 is the initial acquisition phase over
the ﬁrst 1–2 weeks of life. Several studies show that the
microbial composition ﬂuctuates markedly from day to
day (96, 97) and even from hour to hour (98) within each
infant during this perinatal period. Phase 2 starts about
the end of the second week until the introduction of
supplementary feedings of any kind. In this phase the
microbiota composition of breast-fed and formula-fed
infants is quite diﬀerent. Fluctuations within each infant
are far less marked than in phase 1, except when the
feeding regime is switched from exclusively breastfeeding
to a combination with formula-feeding (99). Phase 3 is the
introduction of solids. During this phase the microbiota
of breast-fed infants diversiﬁes and diﬀerences between
breast-fed and formula-fed infants are lost. Phase 4
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begins when weaning is completed. This phase represents
the period of conversion to adult microbiota patterns.
Phases 1 and 3 are thus the phases of greatest time-to-
time ﬂuctuations in gut microbiota composition within
each infant. Furthermore, the introduction of solids starts
for most infants between 3 and 6 months of life. The start
of phase 3 is thus diﬀerent for every infant. Altogether,
the most optimal timing to analyze the gut microbiota
seems to be during phase 2 (2 weeks to 3 months), and
thereafter during phase 4.
Atopic outcomes
One of the diﬃculties in assessing the role of the gut
microbiota, as well as other determinants, for the
inception of allergic and wheezing illnesses is the
heterogeneity of atopic conditions (100). It is generally
known that not all children with a clinical phenotype of
(atopic) eczema are actually sensitized against allergens
(101–103). This has led to the idea that there may exist
at least two variants of eczema, an atopic and a non-
atopic variant (103, 104). If this idea holds true, studies
focusing solely on a clinical phenotype of atopic
dermatitis may underestimate associations since the
eﬀect of the intestinal microbiota may be diﬀerent for
these two types of eczema. This may as well apply for
other atopic symptoms, as non-IgE mediated rhinitis,
wheeze and asthma have also been reported (105, 106).
Furthermore although eczema, asthma and allergic
rhinitis tend to cluster in the same individuals and
families, the exact relationship over time is far from
clear. The question whether eczema is a risk factor
for asthma in a progressive atopic march or that a
co-manifestation of two phenotypes at an early age
exists, remains to be resolved (101, 107).
The studies conducted so far on the association
between the gut microbiota and atopic outcomes have
focused on a variety of outcomes: 10 studies analyzed
both allergic sensitization and clinical symptoms (of
which ﬁve on AD/eczema, two on recurrent wheeze, one
on allergic rhinitis and two on several atopic symptoms);
2 studies investigated allergic sensitization only; and ﬁve
studies clinical symptoms only (four AD/eczema and one
several atopic outcomes). The variety of outcomes used in
the diﬀerent studies is one of the main reasons why
comparing results is diﬃcult. If future longitudinal
population studies examine the association of the gut
microbiota composition with both allergic sensitization
and diﬀerent atopic phenotypes, this could provide
further insight into the role of the gut microbiota in the
etiology of childhood atopy.
Confounding effects
To prevent a potential confounding eﬀect, some studies
chose to exclude certain subgroups: e.g. the exclusion of
infants born by cesarean section or those treated with
antibiotics to prevent a confounding eﬀect of mode of
delivery and antibiotic use (68, 75, 82). Other studies
veriﬁed an association between certain potential con-
founders and (markers of) the gut microbiota (74) or
the disease status (73, 76), or just reported that both
allergic and non-allergic infants were comparable
regarding dietary or other potential confounding
factors. Matching on potential confounding variables
was performed in at least one study (78). Overall most
studies only took one or few potential confounders into
account and only one study, so far, performed multi-
variate analysis (82). Because of the limited population
sizes, most studies lack the power to perform multi-
variate analysis including several confounders. How-
ever, although adjusting for confounders is important it
can be argued whether factors such as mode of
delivery, type of infant feeding and antibiotic use are
true confounders. These factors are not independently
associated with the gut microbiota composition, but
determine it (partly) (108–110). Therefore these factors
are more likely to be distal determinants in the
relationship between the gut microbiota and atopy,
rather than confounders. As a consequence, it is
unlikely that the studies not adjusting to these deter-
minants are biased.
Recent observational studies on the gut microbiota and
allergy may, however, be susceptible to a new type of
confounding, namely confounding by indication with
respect to probiotic or prebiotic use. The increasing
attention in the media on the potential health eﬀects
of probiotics and prebiotics may introduce this kind of
confounding. Allergic mothers may be more aware of the
potential beneﬁcial eﬀects of probiotics and prebiotics
and may therefore more often consume these products
themselves during pregnancy and/or feed them to their
children, in order to prevent the development of allergy in
their oﬀspring. Consequently the eﬀect of the gut
microbiota on the development of allergy will be
confounded by a family history of allergy (confounding
by indication). Confounding by indication because of a
family history of allergic manifestations can best be
controlled for by considering allergy in parents and
siblings as separate confounding variables (111). Another
important reason to adjust for a parental history of
allergy is to limit the chance of reverse causation, as will
be discussed in the subsequent section.
Reverse causation
Most studies conducted so far were cross-sectional. Such
studies obviously cannot exclude the possibility that
diﬀerences in the gut microbiota between healthy and
allergic subjects are the result of the disease itself or the
consequence of the use of medication or changes in diet
or lifestyle by allergic subjects. Longitudinal studies on
the other hand demonstrate that perturbations in the gut
microbiota actually precede the development of atopic
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manifestations, however they still cannot exclude that
early diﬀerences in intestinal microbiota are a conse-
quence of a underlying predisposition toward atopy,
rather than the cause of disease (78). It is thus possible
that diﬀerences in the gut microbiota and diﬀerences in
the development of immunity are consequences of one or
more other unknown factors, associated with the atopic
genotype (68). Only experimental studies in animals or
humans can completely settle this issue. Clinical trials
using probiotics in the treatment or prevention of atopy
for example are capable of demonstrating a causative
eﬀect of bacteria and can gain more insight into the
underlying mechanisms. However these studies can give
no information as to whether perturbations in the
indigenous microbiota themselves can explain the epi-
demic of atopic diseases.
Observational studies can at least partly deal with the
possibility that diﬀerences in the gut microbiota are
caused by factors associated with the atopic genotype,
namely by controlling for a positive family history of
atopic diseases. Until now only three studies were
prospective. One of these prospective studies was based
upon a high-risk population [father, mother and/or older
sibling(s)] having an atopic disease (76), thereby indirectly
taking the possible eﬀect of a positive family history into
account. In one of the other prospective studies, the
KOALA study, multivariate analyses were used to
account among others for parental and sibling allergy.
In two cross-sectional studies, the potential eﬀect of a
positive family history was taken into account by
matching for this factor (78, 79).
Future perspectives
The best way to gain more insight into the association
between the gut microbiota and atopic diseases is
probably to conduct large-scale prospective birth cohort
studies, in which the gut microbiota can be studied in
early infancy and infants can be followed up for
the development of atopic symptoms and sensitization.
The introduction of molecular techniques has simpliﬁed
the analyses of the gut microbiota in large-scale studies as
fecal samples can be frozen prior to the analyses.
Furthermore these molecular techniques provide more
accurate and sensitive results compared with traditional
culture. In such large-scale prospective studies, diﬀerent
atopic outcomes and sensitization can be studied sepa-
rately, thereby leading to more insight into the etiology of
atopy and atopic disorders. Currently several prospective
studies such as the IMPACT Study (112) and the
Allergyﬂora project, are examining the association
between intestinal colonization in infancy and develop-
ment of atopic diseases. Results of these studies are
expected to be available soon.
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